Triptans for the Management of Migraine

Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005 Dec; 6(6): 429–40 Stewart WF, Wood C, Reed ML, et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008; 28: 1170–8 Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc 2009; 84(5): 436–45 Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–9 Bigal ME, Ferrari M, Silberstein SD, et al. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 2009 Jan 21; 49 Suppl. 1: S21–33 Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009 May; 65(5): 491–8 Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebro-vascular system. J Headache Pain 2008; 9: 5–12 Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitization. Lancet Neurol 2009; 8: 679–90 Cutrer FM, Charles A. The neurogenic basis of migraine. Headache 2008 Oct; 48(9): 1411–4 Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT 1B/1D receptor agonists. Arch Neurol 2002; 59: 1084–8 Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75 Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007 Nov; 27(11): 1293–300 Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003; 61(2-A): 313–20 Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007; 47: 1152–68 Pierce M, Marbury T, O’Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009 Jun;49(6): 817–25 Rapoport AM, Tepper SJ, Bigal ME, et al. The triptans formulations: how to match patients and products. CNS Drugs 2003; 17(6): 431–47 Rapoport AM, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache 2006; 46 Suppl. 4: S192–201 Peterlin BL, Rapoport A. Clinical pharmacology of the serotonin receptor agonist zolmitriptan. Expert Opin Drug Metab Toxicol 2007; 3(6): 899–911 Torres G. Zolmitriptan offers doctors and patient choices for effective treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 190–8 Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo controlled comparison to sumatriptan. Neurology 2000; 54: 156–63 Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2008; 4(1): 49–54 Allen C. Rizatriptan: clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 199–205 McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; (3): CD002915 Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100mg tablets utilizing an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract 2008 Dec; 62(12): 1889–99 Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008; 48: 236–47 Becker WJ. Zolmitriptan versus sumatriptan comparison trial. Headache 2001; 41: 321–3 Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007; 115: 34–40 Dowson AJ, Charlesworth BR, Green J, et al. Zolmitriptan nasal spray exhibits good long term safety and tolerability in migraine: results of the INDEX trial. Headache 2005; 45: 17–24 Hedlund C, Rapoport A, Dodick D, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. Headache 2009; 49: 1315–23 Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache 2009 Feb; 49 Suppl. 1: S3–20 Cady RK, Goldstein J, Silberstein S, et al. Expanding access to triptans: assessment of clinical outcome. Headache 2009; 49(10): 1402–13 Lambert GA. Preclinical neuropharmacology of naratriptan. CNS Drug Rev 2005; 11(3): 289–316 Massiou H. Naratriptan. Curr Med Res Opin 2001; 17 Suppl. 1: s51–3 Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002 Jun; 97(3): 247–57 Pascual J. Almotriptan in triptan naýve patients: new evidence of benefits. Cephalalgia 2008; 28 Suppl. 2: 14–20 Chen LC, Ashcroft DM. Meta analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007; 47: 1169–77 Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract 2006 Jun; 60(6): 698–706 Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008; 21: 331–7 Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008; 28 Suppl. 2: 21–7 Williams P, Reeder CE. A comparison of the cost effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004; 10(3): 259–65 Von Seggern RL. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability. Am J Manag Care 2002; 8: S74–9 Sandrini G, Färkkilä M, Burgess G, et al., Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002 Oct 22; 59(8): 1210–7 Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003; 43: 962–74 Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43(3): 214–22 McCormack PL, Keating GM. Eletriptan: a review of its use in the acute treatment of migraine. Drugs 2006; 66(8): 1129–49 Sheftell FD, Bigal ME, Rapoport AM, et al. Tolerability and efficacy are related after triptan use [abstract]. Cephalalgia 2003; 23: 697 Sheftell FD, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double blind placebo controlled study conducted in the United States. Headache 2003; 43: 202–13 Stark P, Dahlof C, Haughie S, et al. Efficacy, safety, and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002; 22: 23–32 Rapoport AM, Ryan R, Goldstein G, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002; 42 Suppl. 2: S74–83 Brandes JL, Smith T, Diamond M, et al. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache 2007; 47: 886–94 Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002; 42 Suppl. 2: S93–9 Dodick DW, Martin VT, Smith T, et al. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 Suppl. 1: s20–30 Tomita M, Suzuki N, Igarashi H, et al. Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection. Intern Med 2002; 41: 622–5 Salonen R. Naratriptan: the gentle triptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 228–35 Feleppa M, Apice G, D’Alessio A, et al. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia 2008; 28: 1012–6 Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004; 24: 417–24 Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007; 21(1): 73–82